...
首页> 外文期刊>Chemico-biological interactions >Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex vivo exposure to soman.
【24h】

Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex vivo exposure to soman.

机译:口服吡啶斯的明溴化物和石杉碱甲可保护人全血胆碱酯酶免于离体暴露于梭曼。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Cholinesterases (ChEs) are classified as acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) according to their substrate specificity and sensitivity to selected inhibitors. The activities of AChE in red blood cells (RBC-AChE) and BChE in serum can be used as potential biomarkers of suppressed and/or heightened activity in the central and peripheral nervous systems. Exposure to organophosphate (OP) chemical warfare agents (CWAs), pesticides, anesthetics, and a variety of drugs such as cocaine, as well as some neurodegenerative and liver disease states, selectively reduces AChE or BChE activity. In humans, the toxicity of pesticides is well documented. Therefore, blood cholinesterase activity can be exploited as a tool for confirming exposure to these agents and possible treatments. Current assays for measurement of RBC-AChE and serum BChE require several labor-intensive processing steps, suffer from wide statistical variation, and there is no inter-laboratory conversion between methods. These methods, which determine only the serum BChE or RBC-AChE but not both, include the Ellman, radiometric, and deltapH (modified Michel) methods. In contrast, the Walter Reed Army Institute of Research Whole Blood (WRAIR WB, US Patent #6,746,850) cholinesterase assay rapidly determines the activity of both AChE and BChE in unprocessed (uncentrifuged) whole blood, uses a minimally invasive blood sampling technique (e.g., blood from a finger prick), and is semi-automated for high-throughput using the Biomek 2000 robotic system. To date, the WRAIR whole blood assay was used to measure AChE and BChE activities in human blood from volunteers in FDA clinical trials. In the first FDA study, 24 human subjects were given either 30 mg PB orally (n = 19) or placebo (n = 5). Blood samples were obtained pre-dosing and 2.5, 5, 8, and 24 h post-dosing. The samples were analyzed for AChE and BChE activity using the WRAIR WB robotic system, and for PB concentration by HPLC. We found that maximal inhibition of AChE (26.2%) and concentration of PB (17.1 ng/mL) occurred at 2.5 h post-PB dosing. AChE activity returned to almost 100% of pre-dose values by 6 h. A dose-dependent linear correlation was found between the amount of PB measured in the blood and the inhibition of AChE. Following soman (GD) exposure, recovered AChE activity was similar to levels that were reversibly protected by the PB administration. Therefore, the WRAIR ChE WB data clearly supports the conclusion that PB is an effective pre-treatment drug for nerve agent exposure (GD). In the second FDA human study for the treatment of Alzheimer's disease, the WRAIR ChE WB assay was used to determine the RBC-AChE and serum BChE profile of healthy elderly volunteers receiving Huperzine A. Huperzine A is a plant-derived reversible and selective AChE inhibitor compared to BChE, and is a more potent inhibitor of AChE than PB. Huperzine A is available as a nutraceutical, a natural supplement reported to improve memory, and has a variety of neuroprotective effects. Individuals received an increasing dose regimen of huperzine A (final dose 200 microg after 4 weeks), which produced more than 50% inhibition of RBC-AChE. Huperzine A was well tolerated by these patients at doses that sequestered more RBC-AChE than PB, and thus warrants further study as a prophylaxis for OP poisoning in addition to Alzheimer's therapy. Due to the documented use of OPs by terrorists and in warfare around the globe, Federal, State, and local authorities need a reliable, fast, inexpensive, and standard method for confirming such an assault in order to initiate appropriate containment, decontamination, and treatment measures. This assay is ideal for prescreening military personnel for atypical ChE activities that would preclude their deployment to areas of potential CWA exposure. The WRAIR WB ChE assay will fulfill the requirement for rapid and reliable monitoring of such exposure in military and civilian populations.
机译:根据胆碱酯酶(ChEs)的底物特异性和对所选抑制剂的敏感性,可将其分为乙酰胆碱酯酶(AChE)和丁酰胆碱酯酶(BChE)。红细胞中的AChE(RBC-AChE)活性和血清中的BChE活性可用作中枢和周围神经系统中抑制和/或增强活性的潜在生物标志物。暴露于有机磷酸盐(OP)化学战剂(CWA),杀虫剂,麻醉剂和各种药物(例如可卡因)以及某些神经退行性疾病和肝脏疾病状态,会选择性降低AChE或BChE活性。在人类中,农药的毒性已得到充分证明。因此,血胆碱酯酶活性可以用作确认暴露于这些药物和可能治疗的工具。当前用于测量RBC-AChE和血清BChE的测定方法需要几个劳动密集型的处理步骤,统计差异很大,并且方法之间没有实验室间的转换。这些方法仅确定血清BChE或RBC-AChE,但不能同时确定两者,包括Ellman方法,放射法和deltapH方法(改良的Michel)。相比之下,沃尔特·里德陆军全血研究所(WRAIR WB,美国专利#6,746,850)胆碱酯酶测定法可快速测定未处理(未离心)全血中AChE和BChE的活性,并使用微创血液采样技术(例如,手指刺血),并使用Biomek 2000机器人系统半自动化以实现高通量。迄今为止,在FDA临床试验中,WRAIR全血分析已用于测量志愿者血液中AChE和BChE的活性。在第一个FDA研究中,对24位人类受试者口服30 mg PB(n = 19)或安慰剂(n = 5)。在给药前和给药后2.5、5、8和24小时获得血样。使用WRAIR WB机器人系统分析样品的AChE和BChE活性,并通过HPLC分析PB的浓度。我们发现,在PB给药后2.5小时,对AChE(26.2%)和PB浓度(17.1 ng / mL)产生了最大抑制作用。到6小时,AChE活性恢复到给药前值的几乎100%。发现在血液中测出的PB量与AChE的抑制之间存在剂量依赖性的线性关系。梭曼(GD)暴露后,恢复的AChE活性类似于PB管理可逆保护的水平。因此,WRAIR ChE WB数据清楚地支持了PB是有效的神经毒剂暴露(GD)预处理药物的结论。在FDA的第二项用于治疗阿尔茨海默氏病的人类研究中,WRAIR ChE WB分析用于确定接受石杉碱甲的健康老年志愿者的RBC-AChE和血清BChE谱。石杉碱A是植物来源的可逆性和选择性AChE抑制剂与BChE相比,是一种比PB更有效的AChE抑制剂。石杉碱甲可作为营养保健品获得,据报道是一种天然补品,可改善记忆力,并具有多种神经保护作用。个体接受的石杉碱A剂量增加方案(4周后最终剂量200微克),对RBC-AChE的抑制作用超过50%。这些患者对石杉碱甲的耐受性良好,其螯合的RBC-AChE量高于PB,因此除阿尔茨海默氏病治疗外,有必要进一步研究预防OP中毒。由于恐怖分子和全球战争中有使用OP的文献记录,联邦,州和地方当局需要一种可靠,快速,廉价且标准的方法来确认此类袭击,以便进行适当的围堵,净化和治疗措施。该检测方法非常适合对军事人员进行非典型ChE活动的预筛查,这将阻止他们部署到潜在的CWA暴露区域。 WRAIR WB ChE分析将满足对军事和平民人口中此类暴露进行快速可靠监测的要求。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号